Results 71 to 80 of about 2,234,657 (224)

Pharmacometric evaluation of pre‐referral rectal artesunate in children with severe malaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Parenteral artesunate is the preferred first‐line treatment for severe malaria. Pre‐referral rectal artesunate suppositories are recommended where parenteral treatment is inaccessible. In this study, we compared dihydroartemisinin exposure and model‐predicted early parasite clearance following rectal artesunate and intravenous artesunate in ...
Ayorinde Adehin   +6 more
wiley   +1 more source

High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. [PDF]

open access: yes, 2009
BACKGROUND: Sulphadoxine-pyrimethamine (SP) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants
Gesase Samwel   +54 more
core   +2 more sources

The genomic architecture of antimalarial drug resistance [PDF]

open access: yesBriefings in Functional Genomics, 2019
AbstractPlasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that cause the majority of cases of human malaria, have developed resistance to nearly all known antimalarials. The ability of malaria parasites to develop resistance is primarily due to the high numbers of parasites in the infected person’s bloodstream during the ...
Cowell, Annie N, Winzeler, Elizabeth A
openaire   +2 more sources

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi   +5 more
wiley   +1 more source

The effects of pharmacogenetics on pharmacokinetics of artemisinin-based combinations in malaria patients [PDF]

open access: yes, 2009
Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus Plasmodium. If not treated appropriately, human P. falciparum malaria can quickly become life-threatening, leading to an estimated 900’000 annual deaths globally. Key
Hodel, Eva Maria
core   +1 more source

Pharmacovigilance of antimalarial treatment in Africa: is it possible? [PDF]

open access: yes, 2006
Pharmacovigilance, defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug related problem", is increasingly being recognized in Africa.
Talisuna, Ambrose O   +11 more
core   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood   +7 more
wiley   +1 more source

[Resistance to the antimalarial drugs].

open access: yesRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2016
Malaria is one of the most widespread infectious diseases around the world with 214 million cases and 438,000 deaths in 2015. In the early twentieth century it was described for the first time the resistance to quinine and, since then, drug resistance to antimalarial drugs has spread up to represent a global challenge in the fight and control of ...
Venanzi E., Lopez-Velez R.
openaire   +2 more sources

Fitness costs of resistance to antimalarial drugs

open access: yesTrends in Parasitology, 2008
It has been recently reported that the prevalence of mutations associated with chloroquine resistance declined during the dry season. Fitness costs of drug resistance were suggested to be responsible for reduced survival of mutant parasites, and only parasites surviving chronic infections were transmitted at the onset of the rainy season.
Felger Ingrid, Beck Hans-Peter
openaire   +4 more sources

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Home - About - Disclaimer - Privacy